Cel Sci

CVMNYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$29.374 M

$1.67 +0.60%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$25.4M

Loss-making

Shares outstanding

17,588,987

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#136Genenta Science S.p.A.GNTA$32.6M
#137Quince TherapeuticsQNCX$31.5M
#138Cel SciCVM$29.4M
#139Evaxion A/SEVAX$29.0M
#140Estrella ImmunopharmaESLA$21.8M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Cel Sci, worth $138.0K. Grants and option exercises are excluded.

Geert R. KerstenChief Executive Officer$138.0K
100,000 shares at $1.38 on 25 Aug 2026 · filed 26 Aug 2026

What if Cel Sci were worth as much as…

Open the what-if tool →

Gold $30.3T

$1,721,194

Per share 1,030,655× higher

Bitcoin $1.72T

$97,777.30

Per share 58,549× higher

Nvidia $5.48T

$311,550.52

Per share 186,557× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Cel Sci are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.